Jazz Pharmaceuticals plc
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Renee D. Gala
- Full Time Employees
- 2,890
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Waterloo Exchange Dublin DU Ireland D04 E5W7
- IPO Date
- Jun 1, 2007
- CIK
- 0001232524
- Website
- jazzpharma.com
- Similar Companies
- Business
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ), headquartered in Dublin, Ireland and founded in 2003, develops and commercializes innovative biopharmaceutical products for serious diseases with significant unmet needs, primarily in neuroscience and oncology; its core portfolio includes Xywav and Xyrem (sodium oxybate formulations) for cataplexy and excessive daytime sleepiness in narcolepsy, Epidiolex (cannabidiol oral solution) for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex, Defitelio (defibrotide) for severe hepatic veno-occlusive disease post-hematopoietic stem-cell transplantation, Rylaze (asparaginase erwinia chrysanthemi recombinant) for acute lymphoblastic leukemia, Vyxeos (daunorubicin and cytarabine liposome injection) for therapy-related acute myeloid leukemia and newly diagnosed acute myeloid leukemia, Zepzelca (lurbinectedin) for metastatic small cell lung cancer, Modeyso (vosoritide) for achondroplasia in pediatric patients, and Ziihera (zanidatamab-hrii) for HER2-positive biliary tract cancer; products are marketed in nearly 75 countries across North America, Europe, and select international markets including Australia, Israel, Japan, Canada, and parts of the Middle East and Latin America. Recent developments include FDA approval of Ziihera (zanidatamab-hrii) in November 2024 for biliary tract cancer with ongoing pursuits in HER2-positive breast cancer, a March 2025 definitive agreement to acquire Chimerix for approximately $935 million to bolster its pipeline, an August 2025 exclusive licensing agreement with Saniona for SAN2355 targeting epilepsy and neurological conditions where Jazz leads global development and commercialization, a February 2024 deal with Redx Pharma acquiring global rights to a KRAS inhibitor program for up to $880 million, and a October 2025 research collaboration with Iambic Therapeutics on AI-driven drug discovery. The company maintains manufacturing facilities in Ireland, England and Italy, with significant operations in Palo Alto, Philadelphia, Oxford and Cambridge.
Company News
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?
Engineers Gate Manager LP Reduces Stock Position in Jazz Pharmaceuticals PLC $JAZZ
Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
Jazz Pharmaceuticals plc (JAZZ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences
Jazz Pharmaceuticals plc (JAZZ) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
Jazz Pharmaceuticals plc (JAZZ) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?
JAZZ Rises on Updated OS Results From Gastric Cancer Study
Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA
Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEA
Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
These Analysts Increase Their Forecasts On Jazz Pharmaceuticals